Rybelsus® (semaglutide tablets), also referred to as oral semaglutide, is the world’s first and only oral GLP-1 receptor agonist (GLP-1 RA) and the first ‘protein in a pill’ treatment for diabetes. It provides a novel treatment choice for adults with type 2 diabetes (T2D) to improve glycaemic control with an additional benefit of weight loss, in a convenient once-daily pill. Following 15 years of research and innovation, oral semaglutide is co-formulated with an absorption enhancer (SNAC), which allows it to be taken orally and absorbed from the stomach. In the PIONEER clinical development programme, oral semaglutide 14mg demonstrated significantly greater HbA1c reduction at one year, with the additional benefit of consistent weight reduction, versus treatments using drugs such as sitagliptin, empagliflozin and liraglutide.